Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease
BL Cohen, DB Sachar - Bmj, 2017 - bmj.com
The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …
Risk of cancer in patients with psoriasis on biological therapies: a systematic review
Background Biological therapies are highly effective in psoriasis, but have profound effects
on innate and adaptive immune pathways that may negatively impact on cancer …
on innate and adaptive immune pathways that may negatively impact on cancer …
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 1: treatment and monitoring recommendations
A Nast, C Smith, PI Spuls, G Avila Valle… - Journal of the …, 2020 - Wiley Online Library
This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …
developed following the EuroGuiDerm Guideline and Consensus Statement Development …
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 2: specific clinical and comorbid situations
A Nast, C Smith, PI Spuls, G Avila Valle… - Journal of the …, 2021 - Wiley Online Library
This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …
developed following the EuroGuiDerm Guideline and Consensus Statement Development …
Malignancy risk and recurrence with psoriasis and its treatments: a concise update
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120
million people worldwide. Systemic treatments have significantly improved disease burden …
million people worldwide. Systemic treatments have significantly improved disease burden …
[HTML][HTML] Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry
Information regarding the safety of biological drugs prescribed to psoriasis patients on daily
and long-term bases is insufficient. We used data from the BIOBADADERM registry (Spanish …
and long-term bases is insufficient. We used data from the BIOBADADERM registry (Spanish …
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
Introduction Several risk factors for severe COVID-19 specific for patients with inflammatory
rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence …
rheumatic and musculoskeletal diseases (RMDs) have been identified so far. Evidence …
A review of ocular adverse events of biological anti-TNF drugs
F Nicolela Susanna, C Pavesio - Journal of Ophthalmic Inflammation and …, 2020 - Springer
The recent introduction of biological agents has revolutionized the treatment of chronic
immune-inflammatory diseases; however, this new therapy did not come without significant …
immune-inflammatory diseases; however, this new therapy did not come without significant …
Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus …
Background Anti–tumor necrosis factor (TNF) therapy in psoriasis has been associated with
an increased risk of serious infections compared with nonbiologic systemic therapies …
an increased risk of serious infections compared with nonbiologic systemic therapies …
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis …
Background Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with
psoriasis or psoriatic arthritis (PsA) on systemic therapy might be at an increased risk for HZ …
psoriasis or psoriatic arthritis (PsA) on systemic therapy might be at an increased risk for HZ …